IJCEMR
The Evaluation of Liraglutide Combined with Intensive Insulin Therapy on the Pancreatic Beta Cells Function in Type II Diabetes Mellitus
TOTAL VIEWS: 6198
Abstract
Objective: The purpose of this study was to analyze the effect of liraglutide administration combined with intensive insulin therapy on the pancreatic β cell function and blood lipid in patients with type 2 diabetes mellitus (T2DM). Methods: The patients with T2DM admitted to our hospital from August 2017 to December 2019 were selected as study subjects. According to the treatments, a total of 200 patients were randomly divided into control group (n = 70) and observation group (n = 130). The patients in the control group were treated with glimepiride combined with intensive insulin therapy. The patients in the observation group were given liraglutide combined with intensive insulin therapy. The changes of body weight and β cell function of patients was compared and analyzed between the two groups. Results: The values of body weight, abdominal circumference and body mass index for patients in the control group revealed no significant difference after treatment compared to non-treatment (P>0.05), but these values in the observation group showed significant decline after treatment (P<0.05). The two groups indicated an obvious decrease on the triglyceride (TG), Total cholesterol (TC), and Low density lipoprotein (LDL), and a significant increase on the high density lipoprotein (HDL) after treatment (P<0.05). In addition, these values in the observation group were superior to that in the control group (P<0.05). There was a decline on the fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), and homeostasis model assessment-insulin resistance (HOMA-IR), and a significant increase on the homeostasis model assessment-β (HOMA-β) in both groups after treatment (P<0.05). But these changes were more obviously in the observation group (P<0.05). Conclusion: Liraglutide administration combined with insulin intensive therapy were contributed to improving β cell function, and reducing blood lipid and body weight.
References
[1] A. M. Schmidt. (2018). “Highlighting Diabetes Mellitus: The Epidemic Continues.” Arterioscler Thromb Vasc Biol., vol. 38, no. 1, pp. e1-e8, 2018.
[2] A. American Diabetes. (2015). “(2) Classification and diagnosis of diabetes.” Diabetes Care, vol. 38, Suppl, pp. S8-S16, 2015.
[3] P. Zimmet, K. G. Alberti, D. J. Magliano, and P. H. Bennett. (2016). “Diabetes mellitus statistics on prevalence and mortality: facts and fallacies.” Nat Rev Endocrinol, vol. 12, no. 10, pp. 616-622, 2016.
[4] K. T. Kao and M. A. Sabin. (2016). “Type 2 diabetes mellitus in children and adolescents.” Aust Fam Physician, vol. 45, no. 6, pp. 401-406, 2016.
[5] Y. Zheng, S. H. Ley, and F. B. Hu. (2018). “Global aetiology and epidemiology of type 2 diabetes mellitus and its complications.” Nat Rev Endocrinol, vol. 14, no. 2, pp. 88-98, 2018.
[6] M. Hanefeld, H. Fleischmann, T. Siegmund, and J. Seufert. (2020). “Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update.” Diabetes Ther, vol. 11, no. 8, pp. 1645-1666, 2020.
[7] D. R. Owens. (2013). “Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes.” Diabetes Technol Ther, vol. 15, no. 9, pp. 776-785, 2013.
[8] S. E. Inzucchi, R. M. Bergenstal, J. B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. L. Peters, A. Tsapas, R. Wender, and D. R. Matthews. (2012). “Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).” Diabetologia, vol. 55, no. 6, pp. 1577-1596, 2012.
[9] C. L. Morgan, C. D. Poole, M. Evans, A. H. Barnett, S. Jenkins-Jones, and C. J. Currie. (2012). “What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes.” J Clin En-docrinol Metab, vol. 97, no. 12, pp. 4605-4612, 2012.
[10] M. Ridderstrale, K. R. Andersen, C. Zeller, G. Kim, H. J. Woerle, U. C. Broedl, and E.-R. H. H. S. T. Investigators. (2014). “Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.” Lancet Diabetes Endocrinol, vol. 2, no. 9, pp. 691-700, 2014.
[11] M. Nauck. (2016). “Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.” Diabetes Obes Metab, vol. 18, no. 3, pp. 203-216, 2016.
[12] S. P. Marso, G. H. Daniels, K. Brown-Frandsen, P. Kristensen, J. F. Mann, M. A. Nauck, S. E. Nissen, S. Pocock, N. R. Poulter, L. S. Ravn, W. M. Steinberg, M. Stockner, B. Zinman, R. M. Bergenstal, J. B. Buse, L. S. Committee, and L. T. Investigators. (2016). “Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.” N Engl J Med., vol. 375, no. 4, pp. 311-322, 2016.
[13] N. Rachdaoui. (2020). “Insulin: The Friend and the Foe in the Development of Type 2 Diabetes Mellitus.” Int J Mol Sci., vol. 21, no. 5, 2020.
[14] F. A. M. Al-Omary. (2017). “Gliclazide.” Profiles Drug Subst Excip Relat Methodol, vol. 42, pp. 125-192, 2017.
[15] W. A. Nuffer and J. M. Trujillo. (2015). “Liraglutide: A New Option for the Treatment of Obesity.” Pharmacotherapy, vol. 35, no. 10, pp. 926-934, 2015.
[16] P. M. O'Neil, A. L. Birkenfeld, B. McGowan, O. Mosenzon, S. D. Pedersen, S. Wharton, C. G. Carson, C. H. Jepsen, M. Kabisch, and J. P. H. Wilding. (2018). “Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.” Lancet, vol. 392, no. 10148, pp. 637-649, 2018.
[17] C. Tzanetakos, A. Melidonis, C. Verras, G. Kourlaba, and N. Maniadakis. “Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin or Exenatide in Patients With Inadequately Controlled Type 2 Diabetes On Oral Antidiabetic Drugs In Greece.” Value Health, vol. 17, no. 7, p. A345, 2014.
[18] N. Peradze, O. M. Farr, N. Perakakis, I. Lazaro, A. Sala-Vila, and C. S. Mantzoros. (2019). “Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial.” Cardiovasc Diabetol, vol. 18, no. 1, p. 141, 2019.
[19] Y. R. Wu, X. Y. Shi, C. Y. Ma, Y. Zhang, R. X. Xu, and J. J. Li. (2019). “Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway.” Cardiovasc Diabetol, vol. 18, no. 1, p. 146, 2019.
[20] M. Fan, H. Jiang, Y. Zhang, Y. Ma, L. Li, and J. Wu. (2018). “Liraglutide Enhances Autophagy and Promotes Pancreatic beta Cell Proliferation to Ameliorate Type 2 Diabetes in High-Fat-Fed and Streptozotocin-Treated Mice.” Med Sci Monit, vol. 24, pp. 2310-2316, 2018.
[21] M. Li, Y. Yang, D. Jiang, M. Ying, Y. Wang, and R. Zhao. (2017). “Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis.” Medicine (Baltimore), vol. 96, no. 39, p. e8161, 2017.
How to cite this paper
The Evaluation of Liraglutide Combined with Intensive Insulin Therapy on the Pancreatic Beta Cells Function in Type II Diabetes Mellitus
How to cite this paper: Shenjiao Dong, Feixia Shen. (2021) The Evaluation of Liraglutide Combined with Intensive Insulin Therapy on the Pancreatic Beta Cells Function in Type II Diabetes Mellitus. International Journal of Clinical and Experimental Medicine Research, 5(3), 377-382.
DOI: http://dx.doi.org/10.26855/ijcemr.2021.07.023
More Articles
- Does Enjoyment in Life Improve the Lipid Profile of Caregivers?
- The Origins and Social Implications of COVID-19: The Need for a Critical Approach and Discussion from the Society
- The Mechanism of Action of Huai-Hua Powder in the Treatment of Anal Fissures: A Study Based on Network Pharmacology and Molecular Docking Techniques
- Pharmacogenomic Application in HER2-positive Breast Cancer
- The History and Application of “Ashi Points”
- In Shortly about Skin Pathology